天美传媒

Antonio Giordano, MD, PhD, is an oncologist and geneticist, as well as founder and president of the Sbarro Health Research Organization and director of the Sbarro Institute for Cancer Research and Molecular Medicine at Temple University in Philadelphia, Pennsylvania. He works on molecular therapeutics and also studies the connections between obesity and cancer. Antonio Giordano grew up in Naples, Italy, where his father, Giovan Giacomo Giordano, was an oncologist and pathologist at the National Cancer Institute of Naples and a professor at the University of Naples. Giordano decided to branch out and start a career in research that was more oriented towards genetics applied to pathology. Early on, while following his father's research, he became interested in the link between the effect of toxic waste on the environment and the increasing cancer rates in the Campania region in Italy. Giordano earned his medical degree at the University of Naples in 1986, and his doctorate at the University of Trieste in 1990. He has published over 600 papers on gene therapy, cell cycle, genetics of cancer, and epidemiology. His early research includes seminal work done in 1989, demonstrating the importance of cell cycle proteins in the functioning of DNA tumor viruses. The transforming gene products of these viruses, such as the E1A oncoproteins of adenovirus 5, led to the identification of cellular factor p60, known as cyclin A. This research was the first demonstration of a physical link between cellular transformation and the cell cycle, thereby paving the way for the melding of these two areas of research. It also helped to open a very exciting avenue of research involving investigators with expertise in different aspects of growth control and cancer.Giordano’s lab also discovered the tumor suppressor gene RB2/p130 and the cell cycle kinases CDK9 and CDK10, two other key players in cell cycle regulation and cell differentiation. Antonio Giordano is the recipient of the Irving J. Selikoff Award for Cancer Research, the Rotary International Award, and Lions Club Napoli-Europa. He has also received the title of Knight of the Republic and Commander of the Order of Merit of the Italian Republic. At the 25th anniversary of the National Organization of Italian American Women, he was awarded the Cross of Merit Melitense, an honor of the Sovereign Military Order of Malta. www.shro.org www.drantoniogiordano.com

Roswell Park Alliance Foundation Endowed Chair in Cancer Prevention and Senior Vice President of Population Sciences, Roswell Park Cancer Institute

Chair, Department of Urology and Director of Robotic Surgery, Roswell Park Cancer Institute Areas of expertise: Robotic surgery, bladder cancer, prostate cancer

President & CEO, Roswell Park Cancer Institute Areas of expertise: cancer research, vitamin D, immunotherapy, cancer vaccines, genomics, personalized medicine, cancer therapies, medical research

Waldemar J. Kaminski Endowed Chair of Pediatrics, Roswell Park Cancer Institute Areas of expertise: pediatric cancers, children’s cancer, Hodgkin lymphoma, pediatric leukemia, cancer therapies

Chief Medical Officer, Roswell Park Cancer Institute Areas of expertise: Liver cancer, pancreatic cancer, abdominal tumors, stomach cancer, gallbladder cancer, gastrointestinal cancer

Director of the Blood and Marrow Transplant Center, Roswell Park Cancer Institute Areas of expertise: Bone marrow transplant, leukemia, lymphoma, multiple myeloma, blood cancer, hematologic oncology

Dr. Carl D. Morrison joined the faculty of Roswell Park Comprehensive Cancer Center in January 2007, and is currently the Senior Vice President of Scientific Development and Integrative Medicine; Director of the Pathology Resource Network; Clinical Chief, Department of Pathology & Laboratory Medicine; Director, Division of Molecular Pathology, and Professor of Oncology. Prior to coming to Roswell Park, Dr. Morrison spent five years as faculty at The Ohio State University Medical Center after completing his residency there in Anatomic Pathology. Dr. Morrison is a board-certified pathologist with a Certificate of Qualification in Oncology in NYS who has an interest in both clinical and research areas. As Senior Vice President of Scientific Development and Integrative Medicine, Dr. Morrison supports the development of new core capabilities and technology platforms in order to conduct highly integrative research across both the basic sciences and clinical care. Dr. Morrison continues to lead the Pathology Resource Network (PRN) at Roswell Park. The overall goal of the PRN is to facilitate access to human biospecimens for IRB-approved investigators with an emphasis on translational efforts. The services offered are quite diverse and serve a unique link between the research and clinical arena. Dr. Morrison started and previously directed the Clinical Data Network (CDN) at Roswell Park. The CDN is the organization of clinical data for research purposes utilizing a federated database approach. The primary goal of the CDN is the promotion of translational research at Roswell Park in a non-human subject research setting.

His role as a Clinical Professor of Medicine, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Professor of Medicine and Director of Early Phase Clinical Trials Program in the Department of Medicine at Roswell Park Comprehensive Cancer Center, He is developing novel therapies for patients with cancer. This includes clinical trials from the early pre-clinical phase through phase I/II/III with emphasis on a combination of immune and targeted agents, novel drug design, including histology-agnostic trial development of targeted therapies. He also provides advice on regulatory requirements and necessary steps associated with advancing drugs, devices, and imaging agents toward clinical trials in patients. In his professional career, I have focused both on developing precision medicine agents as well as immunotherapies. In the first-in-human trial of PLX4032/vemurafenib, our team has provided critical PK/PD data that led to the first in class/ first in human FDA-approved BRAF inhibitor. His interest and expertise in immunotherapy started in the early 1990s with animal models of IL-2 and IL-15 cytokines and natural killer cell development, continued with high dose IL-2 studies, and subsequently Phase I-III trials with both CTLA-4 and PD1/PDL-1 checkpoint inhibitors. Our team was instrumental in the development of talimogene laherparepvec, the first in human oncolytic virus therapy for patients with melanoma. Recently, we have explored immunotherapy combinations with targeted agents as well as combinations of oncolytic viruses with checkpoint inhibitors. Our work was instrumental in several FDA approvals of breakthrough anti-cancer drugs (vemurafenib, dabrafenib+trametinib, vemurafenib+cobimetinib, pembrolizumab, talimogene laherparepvec) and resulted in almost 100 manuscripts, including New England Journal of Medicine, Lancet, Journal of Clinical Oncology, JAMA, Nature. I am a member of American Society of Medical Oncology, Society of Immunotherapy in Cancer, ACP, AACR and Society of Melanoma Research and serve as an editor and reviewer for several peer reviewed journals.

Director of Cancer Screening and Survivorship, Roswell Park Cancer Institute Areas of expertise: Lung cancer, cancer screening, cancer early detection, epidemiology, cancer prevention

Neil B. Friedman, M.D., FACS, is Director of The Hoffberger Breast Center at Mercy as well as Medical Director of The Weinberg Center for Women's Health and Medicine at Mercy. As a catalyst for advancing breast cancer treatment, Dr. Friedman has partnered with many prestigious national and local organizations to improve the treatment options for women with breast cancer. Likewise, on a very personal level, he partners with each of his patients and their families to help them face the challenges and triumphs of living with a breast cancer diagnosis. Dr. Friedman led the charge to bring IORT, Intraoperative Radiotherapy, to Mercy making it the first hospital in Maryland to offer this leading-edge technology. Dr. Friedmane began his medical career as Chief Resident at the nationally renowned Memorial Sloan-Kettering Cancer Center in New York. He is a Board Certified breast cancer doctor who is dedicated to the search for a cure for cancer. His team continues to lead breast cancer initiatives and introduce best-in-practice breast care treatment options, including Intraoperative Radiotherapy (IORT), an innovative, single-dose radiation treatment, to patients. Dr. Friedman was named Humanitarian of the Year by the Mildred Mindell Cancer Foundation for his efforts in the fight against breast cancer. He has served as a national spokesperson for breast cancer prevention for major organizations such as Bath & Bodyworks. Dr. Friedman has been the Chairman of the American Cancer Society’s Research Administrative Committee, a member of its Executive and Professional Education Committees, and served on its Board of Directors. He has also been involved with the Susan G. Komen Breast Cancer Foundation. Dr. Friedman leads a team of clinicians devoted to breast cancer education, advocating the latest advancements in diagnosis and treatment of breast cancer at a number of conferences, continuing education forums, and patient seminars. Dr. Neil Friedman remains committed in his career to find optimal treatments for breast cancer. Some of his accomplishments include: • Named a “Top Doc” by Baltimore magazine in the Breast Surgery category • Named Humanitarian of the Year by the Mildred Mindell Cancer Foundation • The Breast Center at Mercy Medical Center first in Maryland to offer IORT Treatment • Research on cancer has been published in American Journal of Public Health(APHA) and the Journal of Immunotherapy

Armando Sardi, M.D., is a respected and renowned Surgical Oncologist who has been honored as a Top Doc in Baltimore magazine multiple times. He serves as Medical Director of The Institute for Cancer Care at Mercy and as Chief of Division of Surgical Oncology at Mercy Medical Center in Downtown Baltimore, Maryland. Dr. Sardi is one of Maryland’s leading surgical oncologists who use Hyperthermic Intraperitoneal Chemotherapy (HIPEC) to treat late-stage, complex cancers of the abdominal region. Dr. Sardi has been performing HIPEC procedures since 1994 and is considered to be among the best doctors using the technique. This advanced heated chemotherapy procedure is often a life-saving treatment option for patients who have exhausted more traditional treatment plans for stomach cancer. Patients have traveled to Mercy Medical Center from points up and down the East Coast to destinations across the U.S., to seek out Dr. Sardi for his cancer expertise in the HIPEC treatment. Dr. Armando Sardi is a man whose professional focus is devoted to medical excellence, research and finding a cure for cancer. For his patients, Dr. Sardi’s personal concern and approach to their care are what helps them gain a positive outlook and confidence to face the challenges ahead. His cheerful smile and kind-hearted laugh immediately put patients at ease. And yet, his unyielding determination to give every patient the best possible chance to overcome their illness that ranks him among the best of the best. When other doctors have told patients there is no hope, Dr. Sardi tries even harder to beat the odds. Thanks to Dr. Sardi, the HIPEC procedure and other leading-edge treatment options, he has given patients so much more than hope. Patient after patient, year after year, have shared their stories at Mercy’s National Cancer Day Survivor Celebration and Mercy's annual Heat It to Beat It fundraising event. There are 3, 5, 10-year cancer survivors – each telling a heartwarming story of hope and survivorship. Dr. Sardi co-chair Mercy’s Cancer Committee and actively participates in The Tumor Board. These efforts allow cancer experts, specialists and key members of the healthcare team to discuss and collaborate on complex cancer cases to learn new and different ways to optimize resources, medical knowledge and treat patients so that long-term results will be improved. Dr. Sardi also plays a key role in the Mercy National Cancer Survivor Day festivities. This joyous and spirited celebration is more than a reunion of cancer survivors, it is a day when Dr. Sardi and the Mercy family rejoice with their patients and loved ones. Together they have been through a long and challenging cancer journey and together they delight in all the possibilities ahead. Dr. Armando Sardi, whose celebrated reputation has garnered local and international acclaim, has earned an international reputation for the advances he has made in the surgical oncology field and for his humanitarian efforts to care for the poor and underserved in third world countries. Dr. Sardi has been distinguished in Colombia, South America as one of the 100 Most Influential Expatriates – an honor received, in part, for the medical care he provides through the non-profit organization, Partners for Cancer Care and Prevention. This organization was the recipient of the Conquer Cancer Foundation's Inaugural International Innovation Grant. Dr. Armando Sardi has been recognized for his research, leadership and compassionate bedside manner. Some of his awards include: “Hispanic Hero Award for Excellence as a Medical/Social Entrepreneur” Presented by USHYEE “Gold Star Teamwork Award” Presented by The Sisters of Mercy in recognition of Gold Star performance Honored by Fusionarte as one of “100 Colombianos” who represent the talent, creativity, and perseverance of Colombia. Bogota, Colombia December 2012 Named by Baltimore Magazine a "Top Doctor" in the Surgical Oncology specialty Named by Castle Connelly Medical Ltd. a "Top Doctor" in Surgery Dr. Sardi founded the annual HEAT IT TO BEAT IT benefit walk in Baltimore to raise awareness about HIPEC and cancer treatment.

Professor Berry has written ten books in all, including Discovering the Soul of Service; On Great Service; Marketing Services: Competing Through Quality; and Delivering Quality Service. He is the author of numerous academic articles and an invited lecturer throughout the world.

Professor Berry鈥檚 teaching and research have been widely recognized with many honors for his contributions, including Fellow of the American Marketing Association (AMA), the Paul D. Converse Award, the AMA/McGraw-Hill/Irwin Distinguished Marketing Educator Award, the Career Contributions to Services Marketing Award from the AMA, the Outstanding Marketing Educator Award from the Academy of Marketing Science, and Fellow of the Academy of Marketing Science.  Texas A&M awarded him the Distinguished Achievement Award in Teaching (1990) and the Distinguished Achievement Award in Research (1996 and 2008), the highest honors bestowed upon its faculty members.  In 2014, he was selected as the inaugural recipient of the Outstanding Doctoral Alumni Award from the Carey School of Business at Arizona State University, and in 2015 the Mays Business School at Texas A&M awarded him the Lifetime Achievement Award for Research and Scholarship. 

A former national president of the American Marketing Association, Dr. Berry founded the Center for Retailing Studies at Texas A&M in 1982 and served as its director through 2000.

Mark is the Queen's Lead of the 拢5M Medical Research Council-Cancer Research UK funded Stratified Medicine in Colorectal Cancer Consortium (S:CORT), a UK-wide consortium investigating novel precision medicine approaches in colorectal cancer(CRC). His international reputation in CRC was instrumental in his leading a Critical Gaps in Colorectal Cancer Research Initiative, recently published in the high impact factor journal Gut; this landmark publication has attracted significant global attention (his podcast had the most 鈥渉its鈥� of any article in the journal)    

Mark is Queen's Lead of the Health Data Research UK Substantive Site, one of only 6 in the UK, which aims to drive innovative precision medicine and public health approaches through the use of Big Data. He is also national lead for Cancer Strategy for HDR-UK. Mark was co-chair of the Cancer Task Team of the Clinical Working Group of the Global Alliance for Genomics and Health (GA4GH), an international cooperative dedicated to effective and responsible sharing of genomic and clinical data. He has authored a number of key papers including a blueprint for cancer date sharing (published in Nature Medicine) and a road map/call to action for a Global Cancer Knowledge Network in the New England Journal of Medicine 

Mark has published over 180 papers in international peer review journals, including key papers in the highest impact journals (New Engl J Medicine, Lancet, Nature Medicine, Lancet Oncology, Cancer Discovery, Nature Comms, Gut etc). He is co-lead of an ambitious proposal to develop a Global Innovation Institute in Belfast which will include the  One Health Innovation Centre (OHIC), the world鈥檚  first Health and Agri-Food Informatics Innovation Centre.  Mark鈥檚 work has been recognised by a number of national/international awards including the Vander Molen Prize for Leukaemia Research, the Ely Lilly Prize, the St Lukes Medal for Cancer Research and the Graves Medal for Medical Research. He is frequently invited as a guest speaker to international conferences and sits on a number of high level boards/committees at European level including the European Alliance for Personalised Medicine, the Scientific Board of the European Cancer Patient Coalition and the European Cancer Organisation (ECCO) Oncopolicy Forum    

Mark has a strong commitment to patient-centred research/care and to addressing cancer inequalities. He was the architect of the European Cancer Patient's Bill of Rights (BoR), a catalyst for change and empowerment tool for cancer patients which he launched in the European Parliament on World Cancer Day 2014. The BoR has been adopted across Europe and led to the 70:35 Vision, 70% survival for all cancer patients in Europe by 2035 which was recently adopted by ECCO, the largest interdisciplinary cancer organisation in Europe. Mark鈥檚 advocacy work was instrumental in the recent decision to include boys in national UK HPV vaccination programmes.  He is also committed to the provision of optimal pathology and laboratory medicine for citizens in resource-limited settings and was senior author of a recent paper in The Lancet as part of The Lancet Series on Pathology and Laboratory Medicine in Low- and Middle- Income Countries. 

Dr. Mielcarek believes that individualizing treatment according to the patient's needs and philosophy, combined with incorporating up-to-date research knowledge, are key ingredients for excellent patient care.
Clinical Expertise

    Blood stem cell and bone marrow transplantation for hematologic malignancies
    Graft-versus-Host Disease (GVHD)

Title

    Medical Director, Adult Blood and Marrow Transplant Program, Seattle Cancer Care Alliance
    Member, Clinical Research Division, Fred Hutch
    Professor of Medicine, Department of Medical Oncology, University of Washington

Education and Training

    MD: Freie Universit盲t Berlin, 1986
    PhD: Freie Universit盲t Berlin, 1987
    Residency: Freie Universit盲t Berlin, Internal Medicine, 1987-1993
    Research Fellowship: Fred Hutchinson Cancer Research Center, 1994-1999
    Residency: University of Washington, Internal Medicine, 1999-2000
    Fellowship: University of Washington, Medical Oncology, 2000-2003

Dr. Anzai is Professor of Radiology at the University of Utah. She completed her Diagnostic Radiology residency and neuroradiology fellowship training at the University of Michigan. In 2000, she moved to the University of Washington, Seattle where she had served as the neuroradiology fellowship director from 2004-2008, subsequently became the section chief in 2008. In 2005, she obtained her MPH from the University of Washington in Health Services funded by GERRAF program and AHRQ K08 award.

Dr. Anzai currently serves as Associate Chief Medical Quality Officer of the University of Utah Health Care. The major goals as the Associate Chief Medical Quality Officer are to improve safety and quality of patient care, to facilitate the process standardization and coordination of care, to implement patient centered outcomes measures that are relevant for each service line, and connect the costs of delivering care with outcome measures in the entire healthcare enterprise. She received the AAMC (Associations of American Medical College) Award for the implementation of Value Driven Outcome tool in 2016.

Dr. Anzai has been a longstanding member of many academic organizations, including ASNR, ASHNR, RSNA, AUR, ACR, and AAWR. She also participated in the large clinical trial including ACRIN trial. She has over 16 years of experience in working as a neuroradiologist in leading academic institutions with a background of health services research. Her area of primary imaging research interest includes head and neck cancer imaging, traumatic brain injury, and neurodegenerative disease. She is also involved in the cost effectiveness and comparative effectiveness of diagnostic tests in various conditions.

Dr. Amy Moore is the Director of Science and Research at GO2 Foundation. Dr. Amy C. Moore is a PhD-trained virologist and cancer researcher and has spent over a decade working on large statewide and multi-institution initiatives in cancer and vaccines. She currently serves as Director of Science & Research for the GO2 Foundation for Lung Cancer and also works closely with GO2 Foundation's sister organization, the Addario Lung Cancer Medical Institute (ALCMI), to build research capacity in emerging areas of concern to the lung cancer community.  

Because of her virology training and position as a leader in the advocacy community, Dr. Moore has become a highly sought-after expert to discuss the intersection of lung cancer and COVID-19. Since early March, she has participated in over half a dozen panel discussions, webinars, and interviews with leading groups such as IASLC, CURE, US News & World Report to discuss the threat COVID-19 presents to patients with lung cancer and how we can mobilize research to understand this risk. 

William S. Raoofi, M.D., is a pain management specialist with The Center for Interventional Pain Medicine at Mercy Medical Center in Baltimore. Dr. William Raoofi utilizes leading-edge treatment options to alleviate and manage chronic pain in patients caused by cancer, orthopedic disorders and related conditions

Dr. William Raoofi is a fellowship-trained physician in Interventional Pain Management. He completed specialized training in the evaluation, diagnosis, and treatment of patients experiencing chronic pain and related symptoms. He utilizes the Center鈥檚 state-of-the-art imaging and diagnostic equipment, along with minimally invasive treatment procedures and techniques to alleviate pain.

Dr. Raoofi has a special interest in neuromodulation 鈥� a form of pain reduction therapy that utilizes technological devices that alter pain signaling in the body to reduce pain and improve function. These types of therapies may include Dorsal Root Ganglion (DRG) Stimulation, Peripheral Nerve Stimulation, and Spinal Cord Stimulation.

Joshua LaBaer is renowned for his work in proteomics and developing biomarker diagnostics. He leads ASU's COVID-19 research efforts. 

As executive director of the Biodesign Institute, his work emphasizes that multidisciplinary factors culminate to disease, suggesting personalized therapies and unique biomarker analysis. His team uses arrays to assess how programmable a protein is. This work also spans into epigenetics, and the capacity to modulate the activity of these proteins.

LaBaer was the founder and director of Harvard's Institute of Proteomics and a chairman of the Virginia G. Piper Center for Personalized Diagnostics. He is an associate editor of the Journal of Proteome Research, a member of the National Cancer Institute's Board of Scientific Advisors, chair of the Early Detection Research Network Steering Committee and recent president of the U.S. Human Proteome Organization.

Chronic inflammation underlies pathologies as seemingly diverse as cancer, allergy, and a festering wound.  My research focuses on discovering the dysfunctional molecular signals and circuitry causing cells to become bad actors, and why some people are more prone to these problems than others.  In the lab we do this by examining signal transduction in cells differentiated from adult stem cells, particularly mast cells, macrophages, immature myeloid cells, and different populations of mesenchymal stem cells. We also use in vivo modeling to observe the consequences of targeting certain pathways in inflammatory diseases.  The lab's broad areas include (1) Mast Cell Biology; (2) Inflammatory Modulation; and (3) Immune Cell Dynamics in Cancer.  Our ultimate goals are to better understand the diversity of innate and adaptive immune responses, and contribute knowledge to more individually tailored approaches for treatment.  

Current projects include:

Signaling networks (esp. TGF-尾1) and differential expression of myeloid cells during inflammation and in response to immunosuppression
Off-label drug uses and novel compounds, such as plant alkaloids and cannabinoids, for healthful resolution of inflammatory responses
Cellular & molecular mechanisms underlying complementary and integrative health practices such as exercise.
Trained immunity (a.k.a. "innate memory") of mast cells in cancer and autoimmunity
Targeting mast cell specific receptors during inflammation

Education
Postdoctoral: Molecular Immunology, Department of Biology, Virginia Commonwealth University, Richmond, VA
Ph.D.:  Anatomy & Neurobiology, Virginia Commonwealth University School of Medicine, Richmond, VA
B.S.: Biology, James Madison University, Harrisonburg, VA

Professional Affiliations:
American Association of Immunologists
Society for Leukocyte Biology
American Association for Anatomy
American Association for the Advancement of Science